Stay updated with breaking news from Major Histocompatibility Complex Class. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Forward-Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 . These slides have been...
Biomarker shows potential to predict immunotherapy benefit for breast cancer patients A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The study demonstrated that this biomarker, a molecule called the Major Histocompatibility Complex Class II protein (MHC-II), has the potential to be a predictor of immunotherapy benefit with two types of breast cancer -- early-stage,...